Dr. Nikolovska-Coleska is an Associate Professor of Pathology, Director of the Molecular & Cellular Pathology Graduate Program at the University of Michigan and Associate Director of Program in Biomedical Sciences at University of Michigan. Her research group focuses on the discovery, design and development of new molecularly targeted therapies for cancer, particularly targeting protein-protein interactions that are involved in programmed cell death and epigenetic regulation. Dr. Nikolovska-Coleska was the recipient of several awards including, Chemical Structure Association Trust (CSA Trust), New Investigator Award from Leukemia Research Foundation, Innovator Award from Harrington Discovery Institute and AACR-Bayer Innovation and Discovery Award. She is an inventor on more than 13 international and US patents and patent applications, contributing to the discovery and development of Debio 1143 (AT-406), a Smac mimetic targeting inhibitors of apoptosis proteins IAPs, which received FDA breakthrough therapy designation for front-line treatment of head & neck cancer. Currently she serves on the Board of Directors of the International Chemical Biology Society (ICBS) and in 2019 was elected President-Elect. Dr. Nikolovska-Coleska received her PhD in pharmaceutical chemistry at the Ss. Cyril and Methodius University, Skopje, Republic of Macedonia, and was a post-doctoral fellow in drug discovery at the University of Michigan.